Nature Reviews Clinical Oncology最新文献_第2页

Extended neoadjuvant dostarlimab provides durable benefit in resectable dMMR solid tumours 延长新辅助dostarlimumab为可切除的dMMR实体瘤提供持久的益处

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-05-07 DOI: 10.1038/s41571-025-01027-9

Peter Sidaway

引用次数: 0

Improving outcomes of patients with pancreatic cancer. 改善胰腺癌患者的预后。

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-05-06 DOI: 10.1038/s41571-025-01019-9

Stephan B Dreyer,Philip Beer,Sunil R Hingorani,Andrew V Biankin

{"title":"Improving outcomes of patients with pancreatic cancer.","authors":"Stephan B Dreyer,Philip Beer,Sunil R Hingorani,Andrew V Biankin","doi":"10.1038/s41571-025-01019-9","DOIUrl":"https://doi.org/10.1038/s41571-025-01019-9","url":null,"abstract":"Research studies aimed at improving the outcomes of patients with pancreatic ductal adenocarcinoma (PDAC) have brought about limited progress, and in clinical practice, the optimized use of surgery, chemotherapy and supportive care have led to modest improvements in survival that have probably reached a plateau. As a result, PDAC is expected to be the second leading cause of cancer-related death in Western societies within a decade. The development of therapeutic advances in PDAC has been challenging owing to a lack of actionable molecular targets, a typically immunosuppressive microenvironment, and a disease course characterized by rapid progression and clinical deterioration. Yet, the progress in our understanding of PDAC and identification of novel therapeutic opportunities over the past few years is leading to a strong sense of optimism in the field. In this Perspective, we address the aforementioned challenges, including biological aspects of PDAC that make this malignancy particularly difficult to treat. We explore specific areas with potential for therapeutic advances, including targeting mutant KRAS, novel strategies to harness the antitumour immune response and approaches to early detection, and propose mechanisms to improve clinical trial design and to overcome various community and institutional barriers to progress.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"38 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143914984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab 非小细胞肺癌中不断发展的免疫血管生成模式：来自ivonescimab的经验教训

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-05-06 DOI: 10.1038/s41571-025-01024-y

Roy S. Herbst, Lieping Chen

引用次数: 0

Less-frequent surveillance is noninferior to annual mammography. 监测频率较低的乳房 X 射线照相术并不比每年一次的乳房 X 射线照相术效果差。

IF 81.1 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-05-01 DOI: 10.1038/s41571-025-01001-5

Peter Sidaway

引用次数: 0

Durable responses to belzutifan in patients with VHL disease VHL患者对贝祖替芬的持久反应

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-25 DOI: 10.1038/s41571-025-01023-z

Peter Sidaway

引用次数: 0

Sacituzumab tirumotecan improves OS in mTNBC 萨妥珠单抗替鲁莫替康可改善mTNBC的OS

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-23 DOI: 10.1038/s41571-025-01022-0

David Killock

引用次数: 0

FDA approvals in 2024: new options for patients across cancer types and therapeutic classes 2024年FDA批准：不同癌症类型和治疗类别的患者的新选择

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-11 DOI: 10.1038/s41571-025-01018-w

Sundeep Agrawal, Esther Park, Paul G. Kluetz

引用次数: 0

Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma MRD评估在多发性骨髓瘤临床治疗中的机遇与挑战

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-07 DOI: 10.1038/s41571-025-01017-x

Bruno Paiva, Qian Shi, Noemi Puig, Maria-Teresa Cedena, Alberto Orfao, Brian G. M. Durie, Nikhil C. Munshi, Jesús San-Miguel

{"title":"Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma","authors":"Bruno Paiva, Qian Shi, Noemi Puig, Maria-Teresa Cedena, Alberto Orfao, Brian G. M. Durie, Nikhil C. Munshi, Jesús San-Miguel","doi":"10.1038/s41571-025-01017-x","DOIUrl":"https://doi.org/10.1038/s41571-025-01017-x","url":null,"abstract":"Measurable residual disease (MRD) assessment is, from the methodological point of view, ready for prime time in multiple myeloma (MM). Abundant evidence underscores the value of MRD status determined using highly sensitive next-generation flow cytometry and next-generation sequencing tests in evaluating response to treatment and, therefore, prognosis in patients with this disease. MRD response assessment and monitoring might present a range of opportunities for individualized patient management. Moreover, the considerable amounts of high-quality and standardized MRD data generated in clinical trials have led to the acceptance of MRD negativity as an early end point for accelerated regulatory approval of treatments for MM. The data leave no doubt that the efficacy of new regimens in inducing deeper and durable MRD-negative responses is connected with prolonged survival. Yet, several evidential, technical and practical challenges continue to limit the implementation of MRD-guided treatment strategies in routine practice, and the use of MRD as a surrogate end point remains controversial to some. In this Review, we draw on past and present research to propose opportunities for overcoming some of these challenges, and to accelerate the use of MRD assessment for improved clinical management of patients with MM.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"73 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143789808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HER2 testing: evolution and update for a companion diagnostic assay HER2检测：伴随诊断试验的发展和更新

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-07 DOI: 10.1038/s41571-025-01016-y

Charles J. Robbins, Katherine M. Bates, David L. Rimm

{"title":"HER2 testing: evolution and update for a companion diagnostic assay","authors":"Charles J. Robbins, Katherine M. Bates, David L. Rimm","doi":"10.1038/s41571-025-01016-y","DOIUrl":"https://doi.org/10.1038/s41571-025-01016-y","url":null,"abstract":"Human epidermal growth factor receptor 2 (HER2; encoded by ERBB2) testing has been a cornerstone of patient selection for HER2-targeted therapies, principally in breast cancer but also in several other solid tumours. Since the introduction of HercepTest as the original companion diagnostic for trastuzumab, HER2 assessment methods have evolved substantially, incorporating various testing modalities, from western blots, immunohistochemistry and fluorescence in situ hybridization, to early chromogenic quantitative methods and, probably in the future, fully quantitative methods. The advent of highly effective HER2-targeted antibody–drug conjugates with clinical activity at low levels of HER2 expression, such as trastuzumab deruxtecan, has necessitated the re-evaluation of HER2 testing, particularly for HER2-low tumours. In this Review, we provide an in-depth overview of the evolution of HER2 testing, the current clinical guidelines for HER2 testing across various solid tumours, challenges associated with current testing methodologies and the emerging potential of quantitative techniques. We discuss the importance of accurately defining HER2-low expression for therapeutic decision-making and how newer diagnostic approaches, such as quantitative immunofluorescence and RNA-based assays, might address the limitations of traditional immunohistochemistry-based methods. As the use of HER2-targeted therapies continues to expand to a wider range of tumour types, ensuring the precision and accuracy of HER2 testing will be crucial for guiding treatment strategies and improving patient outcomes.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"34 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143797879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers MSI-H/dMMR癌症的流行病学、发病机制、生物学和进化管理

IF 78.8 1区医学

Nature Reviews Clinical Oncology Pub Date : 2025-04-03 DOI: 10.1038/s41571-025-01015-z

Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio

{"title":"Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers","authors":"Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb, Filippo Pietrantonio","doi":"10.1038/s41571-025-01015-z","DOIUrl":"https://doi.org/10.1038/s41571-025-01015-z","url":null,"abstract":"Deficiency in DNA mismatch repair (dMMR) is a common pathway of carcinogenesis across different tumour types and confers a characteristic microsatellite instability-high (MSI-H) molecular phenotype. The prevalence of the MSI-H/dMMR phenotype is highest in endometrial and colorectal cancers, and this phenotype is associated with a distinct tumour biology, prognosis and responsiveness to various anticancer treatments. In a minority of patients, MSI-H/dMMR cancers result from an inherited pathogenic variant in the context of Lynch syndrome, which has important implications for familial genetic screening. Whether these hereditary cancers have a different biology and clinical behaviour to their sporadic counterparts remains uncertain. Interest in this tumour molecular subtype has increased following the discovery of the high sensitivity of metastatic MSI-H/dMMR cancers to immune-checkpoint inhibitors (ICIs) in a histology-agnostic manner, which reflects the genomic hypermutation resulting from dMMR that renders these tumours highly immunogenic and immune infiltrated. This vulnerability is now also being exploited in early stage disease settings. Despite this common biological foundation, different MSI-H/dMMR cancers have histotype-specific features that correspond to their particular cell or tissue of origin, which might be associated with differences in prognosis and sensitivity to ICIs. In this Review, we provide an overview of the epidemiology, biology, pathogenesis, clinical diagnosis and treatment of MSI-H/dMMR tumours as a histology-agnostic cancer phenomenon. We also highlight peculiarities associated with specific pathogenetic alterations and histologies of MSI-H/dMMR tumours.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"37 1","pages":""},"PeriodicalIF":78.8,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0